Physician profile
Brian Feldman
NPI 1336243716
$3,736.62
in general payments reported to CMS, 2019-2025
22 companies · $638 in 2025
The $638 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $170 · 2021: $322 · 2022: $642 · 2023: $500 · 2024: $619 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $763.59 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $396.70 | 2019-2025 | Austedo, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $391.35 | 2019-2025 | Trintellix |
| Alkermes, INC. | $288.78 | 2021-2025 | Lybalvi, Aristada |
| Bausch Health US, LLC | $287.86 | 2019-2025 | Aplenzin |
| Neurocrine Biosciences, INC. | $186.31 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176.95 | 2022-2025 | Caplyta |
| Lundbeck LLC | $170.26 | 2019-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $164.65 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $142.61 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $142.26 | 2019-2024 | Rexulti, Abilify Maintena |
| Allergan, INC. | $130.53 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $114.94 | 2019 | |
| Abbvie INC. | $94.47 | 2022-2024 | |
| Axsome Therapeutics, INC. | $67.01 | 2024-2025 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $53.73 | 2024 | |
| Alfasigma USA, INC. | $36.69 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $33.58 | 2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $31.51 | 2019 | |
| Livanova USA, INC. | $24.65 | 2021 | |
| Acadia Pharmaceuticals INC | $20.61 | 2023 | Nuplazid |
| Neuronetics, INC. | $17.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.